Showing 1 - 4 results of 4 for search 'Christine Hanoun', query time: 0.02s Refine Results
  1. 1
    Risk prediction in diffuse large B-cell lymphoma improves when combining baseline PET features with interim PET response

    Risk prediction in diffuse large B-cell lymphoma improves when combining baseline PET features with interim PET response by Jakoba J. Eertink, Martijn W. Heymans, Sanne E. Wiegers, Annelies L. Bes, Ulrich Duhrsen, Andreas Huttmann, Lars Kurch, Sally F. Barrington, George N. Mikhaeel, Pieternella J. Lugtenburg, Luca Ceriani, Emanuele Zucca, Tamas Gyorke, Sandor Czibor, Gerben J.C. Zwezerijnen, Ronald Boellaard, Josee M. Zijlstra, Christine Hanoun

    Published 2025-05-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Cytomegalovirus immunoglobulin serology prevalence in patients with newly diagnosed multiple myeloma treated within the GMMG-MM5 phase III trial

    Cytomegalovirus immunoglobulin serology prevalence in patients with newly diagnosed multiple myeloma treated within the GMMG-MM5 phase III trial by Hans Salwender, Niels Weinhold, Axel Benner, Kaya Miah, Maximilian Merz, Mathias Haenel, Christian Jehn, Elias Mai, Ekaterina Menis, Igor Blau, Christof Scheid, Dirk Hose, Anja Seckinger, Steffen Luntz, Britta Besemer, Markus Munder, Peter Brossart, Bertram Glass, Hans-Walter Lindemann, Katja Weisel, Christine Hanoun, Paul Schnitzler, Sarah Klemm, Hartmut Goldschmidt, Marc Raab, Ahmet Elmaagacli

    Published 2024-12-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Bortezomib before and after high‐dose therapy in transplant‐eligible patients with newly diagnosed multiple myeloma: Long‐term overall survival after more than 10 years of follow‐up from the phase III HOVON‐65/GMMG‐HD4 trial

    Bortezomib before and after high‐dose therapy in transplant‐eligible patients with newly diagnosed multiple myeloma: Long‐term overall survival after more than 10 years of follow‐u... by Elias K. Mai, Axel Nogai, Henk M. Lokhorst, Bronno van derHolt, Sonja Zweegman, Katja C. Weisel, Sandra Croockewit, Anna Jauch, Jens Hillengass, Marian Stevens‐Kroef, Marc S. Raab, Annemiek Broijl, Gerard M. J. Bos, Peter Brossart, Paula Ypma, Christine Hanoun, Uta Bertsch, Thomas Hielscher, Hans J. Salwender, Christoph Scheid, Hartmut Goldschmidt, Pieter Sonneveld

    Published 2024-11-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study

    Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study by Maximilian Merz, Anca‐Maria Albici, Bastian vonTresckow, Kristin Rathje, Roland Fenk, Tobias Holderried, Fabian Müller, Natalia Tovar, Aina Oliver‐Cáldes, Vladan Vucinic, Soraya Kharboutli, Ben‐Niklas Bärmann, Francis Ayuk, Uwe Platzbecker, Friedrich Stölzel, Nathalie Schub, Friederike Schmitz, David Fandrei, Patrick Born, Cyrus Khandanpour, Christine Hanoun, Keven Hörster, Marcel Teichert, Barbara Jeker, Michele Hoffmann, Nicolaus Kröger, Carlos Fernández de Larrea, Thomas Pabst, Nico Gagelmann

    Published 2025-01-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: